文献速递肾小球疾病慢性肾脏病

巴多索隆甲基在Alport综合征中的效应

Effects of Bardoxolone Methyl in Alport Syndrome.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-11-21

这项2/3期随机对照试验将12-70岁、eGFR 30-90 ml/min/1.73 m2的Alport综合征患者随机分配至巴多索隆甲基组(n=77)或安慰剂组(n=80),评估48周和100周eGFR变化。巴多索隆甲基组相较安慰剂在48周和100周eGFR保持更优,但停药4周后使用全部可用数据的分析中104周差异未达统计学显著。

要点

  • 巴多索隆甲基组48周eGFR较安慰剂组高9.2 ml/min/1.73 m2,100周高7.4 ml/min/1.73 m2。
  • 停药4周后52周和104周eGFR差异分别为5.4和4.4 ml/min/1.73 m2。
  • 无缺失值插补的事后分析中104周差异未达统计学显著(1.5 ml/min/1.73 m2)。

核心结论

  • 在接受标准治疗的青少年和成人Alport综合征患者中,巴多索隆甲基治疗2年期间相较安慰剂保持了eGFR;停药后使用全部可用数据的结果无显著差异。

研究设计与样本

  • 随机对照试验,将12-70岁、eGFR 30-90 ml/min/1.73 m2的Alport综合征患者随机分配至巴多索隆甲基组(n=77)或安慰剂组(n=80)。

主要发现

  • 48周和100周时,巴多索隆甲基组相较安慰剂组的eGFR组间差异分别为9.2(97.5% CI 5.1至13.4;P<0.001)和7.4(95% CI 3.1至11.7;P=0.0008)ml/min/1.73 m2。
  • 停药4周后,52周和104周时对应的eGFR平均差异分别为5.4(97.5% CI 1.8至9.1;P<0.001)和4.4(95% CI 0.7至8.1;P=0.02)ml/min/1.73 m2。
  • 在无缺失eGFR数据插补的事后分析中,104周差异未达统计学显著(1.5 [95% CI -1.9至4.9] ml/min/1.73 m2)。
  • 巴多索隆甲基组治疗中断更频繁,多数因符合方案规定的血清转氨酶升高标准;安慰剂组严重不良事件更频繁。
  • 每组各有3例患者发生肾衰竭。

局限性

  • 停药后使用全部可用数据的结果无显著差异。
  • 无缺失值插补的事后分析中104周差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Alport syndrome is an inherited disease characterized by progressive loss of kidney function. We aimed to evaluate the safety and efficacy of bardoxolone methyl in patients with Alport syndrome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We randomly assigned patients with Alport syndrome, ages 12-70 years and eGFR 30-90 ml/min per 1.73 m2, to bardoxolone methyl (n=77) or placebo (n=80). Primary efficacy end points were change from baseline in eGFR at weeks 48 and 100. Key secondary efficacy end points were change from baseline in eGFR at weeks 52 and 104, after an intended 4 weeks off treatment. Safety was assessed by monitoring for adverse events and change from baseline in vital signs, 12-lead electrocardiograms, laboratory measurements (including, but not limited to, aminotransferases, urinary albumin-creatinine ratio, magnesium, and B-type natriuretic peptide), and body weight. RESULTS: Patients randomized to bardoxolone methyl experienced preservation in eGFR relative to placebo at 48 and 100 weeks (between-group differences: 9.2 [97.5% confidence interval, 5.1 to 13.4; P<0.001] and 7.4 [95% confidence interval, 3.1 to 11.7; P=0.0008] ml/min per 1.73 m2, respectively). After a 4-week off-treatment period, corresponding mean differences in eGFR were 5.4 (97.5% confidence interval, 1.8 to 9.1; P<0.001) and 4.4 (95% confidence interval, 0.7 to 8.1; P=0.02) ml/min per 1.73 m2 at 52 and 104 weeks, respectively. In a post hoc analysis with no imputation of missing eGFR data, the difference at week 104 was not statistically significant (1.5 [95% confidence interval, -1.9 to 4.9] ml/min per 1.73 m2). Discontinuations from treatment were more frequent among patients randomized to bardoxolone methyl; most discontinuations were due to protocol-specified criteria being met for increases in serum transaminases. Serious adverse events were more frequent among patients randomized to placebo. Three patients in each group developed kidney failure. CONCLUSIONS: In adolescent and adult patients with Alport syndrome receiving standard of care, treatment with bardoxolone methyl resulted in preservation in eGFR relative to placebo after a 2-year study period; off-treatment results using all available data were not significantly different. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL (CARDINAL), NCT03019185.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Warady BA, Pergola PE, Agarwal R, et al. Effects of Bardoxolone Methyl in Alport Syndrome. Clin J Am Soc Nephrol. 2022. PMID: 36411058. doi:10.2215/CJN.02400222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。